Targets › CHRM5
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Respiratory, Ophthalmology; next expected readout Oct 2027.
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. (UniProt, P08912)
Open in Phaseline: the race on CHRM5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Glycopyrronium Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor | CHRM3, CHRM1, CHRM4, CHRM2, CHRM5 | Phase 2 | Asthma | May 2029 |
| GenSight Biologics | GS030-DP Recombinant adeno-associated viral vector (rAAV2.7m8) delivering ChrimsonR-tdTomato gene f | CHRM5 | Phase 1 | Non-syndromic Retinitis Pigmentosa | Oct 2027 |
Asthma (1) Non-syndromic Retinitis Pigmentosa (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.